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There  is now  a  considerable body of  evidence demonstrating  that  two  types of 
specific lymphoid cells are involved in the antibody response to a variety of antigens 
(1-10).  One of these cells appears to be derived largely from  the bone marrow cell 
population, to be the direct precursor of antibody-secreting  cells, and to possess mem- 
brane-associated antigen-binding receptors, immunoglobulin in nature and similar (or 
identical) in specificity with  the antibody produced (3,  11-13 and footnote  1).  The 
activation of  these  antibody-forming cell precursors  (AFCP)  2 either  requires  or  is 
markedly enhanced  by  the  activity of  another  specific cell type which  appears  to 
neither secrete detectable immunoglobulin nor to differentiate into an immunoglobu- 
lin-secreting cell (2, 3,  14). This latter cell type has been referred to as a "helper" cell 
and has been shown in the mouse to be derived from  thymus cells and to bear the 
isoantigen ~ (15,  16).  Its activity, although undefined in mechanism, has been dem- 
onstrated  to  be resistant  to  X-irradiation (16a)  and  to  account  for  the  "carrier- 
specificity" of anamnestic antibody responses to hapten-carrier conjugates (8,  15, 17). 
Recent studies in the mouse have demonstrated that specific immunologic toler- 
ance is relatively easy to induce in the helper cell population and that such a state of 
unresponsiveness may also be induced in bone marrow lymphocytes, although in this 
population induction of tolerance is more difficult to achieve and the duration of un- 
1 Davie, J. M., and W. E. Paul. 1971. Receptors o  n immunocompetent cells. II. Specificity 
and nature of receptors on  125I-DNP-GPA  binding lymphocytes of normal guinea pigs. J. 
Exp. Med. In press. 
2ABC,  antigen-binding cells;  AFCP,  antibody-forming cell  precursors;  BCG,  bovine 
gamma globulin; CFA, complete  Freund's adjuvant; o-GL, copolymer of D-glutamic  acid 
and D-lysine; DNFB, 1-fluoro-2,4-dinitrobenzene;  DNP, 2,4-dinitrophenyl; GPA, guinea pig 
albumin;  GVH, graft-versus-host;  L-GL, copolymer  of  L-glutamic  acid  and  L-lysine;  OVA, 
ovalbumin; PFC, indirect plaque-forming  cells; SRBC, sheep  erythrocytes; TNP,  trinitro- 
phenyl. 
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responsiveness  is relatively short (18). Whether tolerance can be induced in mature 
bone marrow-derived cells and whether such induction requires  the participation of 
helper cells has not been established. 
In the studies presented in this paper, we have attempted to approach these 
issues  by utilizing  a  system involving responses to hapten-carrier conjugates 
in guinea pigs. In this system, we have equated the hapten-specific antibody- 
secreting  cell precursors with  the bone marrow-derived AFCP  of the mouse; 
further,  carrier-specific cooperating cells have been assumed to be analogous 
operationally to  the  thymus-derived helper  cells  (7,  8).  We now report  that 
previous  administration  of  2,4-dinitrophenyl  (DNP)  conjugates  of  "nonim- 
munogenic" amino acid copolymers exerts a profound suppressive effect on the 
capacity of guinea pigs to display anti-DNP antibody responses to immuniza- 
tion  with  the  DNP  conjugate  of a  strong  antigen,  DNP-ovalbumin  (OVA). 
Furthermore, this suppression has also been achieved in guinea pigs which have 
been primed with DNP-OVA before administration  of such nonimmunogenic 
conjugates.  Moreover, the hapten-specific unresponsiveness induced  has been 
shown to be central in nature, in that a substantial diminution in numbers of 
anti-DNP  antibody-secreting  and  of  DNP-specific  antigen-binding  cells  is 
observed. 
In  contrast,  administration  of DNP  conjugates  of  a  nonimmunogenic  co- 
polymer will be shown  to  exert a  very different  effect in DNP-OVA-primed 
guinea pigs undergoing graft-versus-host  (GVH)  reactions. As was previously 
demonstrated, the required stimulation of carrier-specific cells for the elicitation 
of anti-hapten secondary responses can be obviated by an appropriately timed 
GVH reaction; thus, induction of GVH reactions in DNP-OVA-primed guinea 
pigs permits the elicitation of marked secondary anti-DNP antibody responses 
to  a  DNP  conjugate  of  an  unrelated  immunogenic  carrier  protein,  bovine 
gamma globulin (BGG)  (19).  Similarly, the nonimmunogenic DNP copolymer 
employed here,  highly tolerogenic under normal circumstances of administra- 
tion,  elicits  striking secondary anti-DNP  antibody responses in primed hosts 
undergoing a  GVH reaction. 
Materials and Methods 
Proteins and Chemical Reagents.--The copolymers of D-glutamic acid and I)-lysine  (D-GL), 
and L-glutamic acid and L-lysine (L-GL) were obtained from Pilot Chemicals, Inc., Water- 
town,  Mass. Average molecular weights were respectively 50,000 and  115,000, and  both 
isomers had  a ratio  of G:L of 60:40. 2,4,6-trinitrobenzenesulfonlc acid (TNP)  was pur- 
chased from Eastman Organic Chemicals, Rochester, N. Y. All other proteins and chemical 
reagents used were, in general, identical with those described in the previous papers in this 
series (7, 8, 19). 
Hapten-Carrier Conjugates.--The following 2,4-dinitrophenyl conjugates were prepared as 
previously  described  (20): DNPs-OVA,  DNP23-BGG, DNP~-GPA,  and  DNPs0-L-GL. 
DNP53-D-GL was prepared by reacting D-GL with 1-fluoro-2,4-dinitrobenzene (DNFB)  un- 
der the following conditions: the D-GL was dissolved in water and the pH was gently raised KATZ~ DAVIE~ PAUL~ AND  BENACERRAF  203 
to 6.5 with 1 ~¢ NaOH. An equal weight of DNFB in p-dioxane was added dropwise over a 
period of 90 rain; the pH of the reaction mixture was slowly increased during this time by the 
addition of 1 N NaOH until a final pH of 8.0 was reached. After 24 hr at room temperature~ 
500 mg of glycyl-glycine was added and the reaction mixture was extensively dialyzed. Sub- 
scripts refer to the average number of moles of DNP per mole of carrier. 
Immunizations.--Adult inbred strain 2 and strain 13 guinea pigs weighing 200-400 g were 
obtained from the Division of Research Services, National Institutes  of Health, Bethesda, 
Md. In general, primary immunization with hapten-carrier conjugates was carried out with 
1.0 mg of conjugate in saline, intraperitoneally  , on 3 successive days. Secondary immuniza- 
tion with hapten-carrier conjugates consisted of 1.0 mg in saline administered  as a  200  #g 
intradermal dose followed 4 hr later by an 800 #g intraperitoneal dose. In the case of strain 13 
guinea pigs, diphenhydromine hydrochloride (Benadryl, Parke, Davis & Co., Detroit, Mich.), 
5.0 mg/kg, was administered intramuscularly 1 hr before the intraperitoneal dose of hapten- 
carrier conjugate as a prophylactic measure against anaphylaxis. Animals were bled just be- 
fore the secondary challenge and at various intervals thereafter; antibody determinations were 
performed as described below.  In certain experiments (see Results), immunization of guinea 
pigs with carrier proteins was carried out by administering, in the footpads, 50 #g of protein 
emulsified  in complete Freund's adjuvant  (CFA, Difco Laboratories, Detroit,  Mich.).  For 
cell transfer  experiments,  donor guinea pigs were immunized  in  the footpads  with  saline 
emulsified  in CFA. 
Several modifications of the general immunization protocol were employed; these are de- 
scribed in the Results section of this paper. 
Antibody Measurements.- 
Measurement  of anti-DNP antibodies: Serum anti-DNP antibody levels were determined 
by a  modified  Farr assay  (21) using 3H-DNP-~-amino-N-caproic acid  (22).  Using standard 
curves as described previously (7), percentage of binding was converted into amount  of anti- 
DNP antibody in micrograms per milliliter. 
Measurement of anti-OVA antibodies: Serum anti-OVA antibody levels were determined by 
the Farr technique  (21) using OVA-125I prepared  as described previously (8,  23).  Antigen- 
binding capacities were determined on the basis  of the serum dilution required to bind 33% 
of a sample of OVA-125I (4/zg/ml). 
Determination  of Hapten-Specific  Antigen-Binding  Cetls.--Cells  in  peripheral  blood  and 
spleen, bearing DNP-specific membrane-associated immunoglobulin, were enumerated  by a 
radioautographic technique recently described in detail elsewhere (24). Briefly, lymphocytes 
were isolated from spleen or heparinized peripheral blood as described previously (24)  and 
suspended in Eagle's minimum essential medium  (10-50 X  106 cells/ml) containing heparin 
(50 units/ml) and sodium azide (1 mg/ml). After  cooling thecells to 4°C, 40 ngof DNP23-GPA- 
125I (specific activity 19/zCi/#g) was added and the mixture was incubated  for 30 rain.  Un- 
bound antigen was removed by washing the cells four times through gradients of fetal bovine 
serum; the cells were smeared on serum-dipped slides, air dried, and fixed for 30 min in meth- 
anol-acetic acid-water (89:1 : 10). Slides were then dipped in Nuclear Track Emulsion (NTB-2, 
Eastman Kodak Co., Rochester, N. Y.)  that had  been diluted  1:2 in water and heated to 
50°C. After appropriate exposure periods (2 days) the radioautographs were developed using 
standard  methods, and lymphocytes were examined for silver grains. 
Determination  of Hapten-Specific  Antibody-Producing  Cdls.--The  frequency  of  cells  in 
spleens  of immunized guinea pigs secreting anti-DNP antibodies was determined by a modi- 
fication of the hemolytic plaque technique (25-27).  For this assay sheep erythrocytes (SRBC) 
were conjugated with TNP as described by Rittenberg and Pratt  (28).  Washed dissociated 
spleen cell suspensions  from individual guinea pigs were assayed for IgG antibody-producing 
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guinea pig ~,~-globulin as facilitating antiserum. It was determined that in the guinea pig 
spleens the background against SRBC is less than 2 PFC/106 cells. 
Cell Transfers.--Donor guinea pigs were immunized in the footpads with saline in CFA. 
3 wk later the animals were sacrificed and axillary, occipital, inguinal, and popliteal lymph 
nodes and spleens  were removed. Single cell suspensions in Eagle's minimum essential medium 
were prepared and washed. 200 X  106 nucleated ceils were transferred intravenously to re- 
cipient guinea pigs. 
Statistical Analysis.--Serum antibody values were logarithmically transformed and means 
and standard errors calculated. Results from appropriate groups were compared by Student's 
t test. In those cases where no specific  antigen binding could be detected in the serum, a value 
of 0.10/~g/ml was arbitrarily assigned in order to permit logarithmic transformation of the 
data. 
RESULTS 
Delineation of the Nonimmunogenic  Nature  of the DNP Copolymers Employed 
DNP conjugates of the copolymer of L-glutamic acid and L-lysine belong to 
a  class of substances to which strain 13  guinea pigs are genetically incapable 
of  responding  immunologically  by  virtue  of  the  absence  of  the  autosomal 
dominant  PLL gene in this  strain  (29,  30).  Although  the precise role of the 
product of the PLL gene is unknown, it appears to exert its function primarily 
in cells mediating cellular immune responses and in helper cells (8, 31). Thus, 
the DNP-L-GL conjugate is operationally nonimmunogenic in strain 13 guinea 
pigs. 
In general, poly-D-amino acids have been shown to be either n°nimmunogenic 
(32)  or very poor immunogens (33). In order to substantiate  the nonimmuno- 
genic  nature  of  the  DNP  conjugate  of  the  copolymer ~)-glutamic  acid  and 
n-lysine in both strain  13 and strain 2 guinea  pigs,  the following studies were 
performed. 
To create the most favorable conditions for eliciting responses to very weak 
immunogens,  strain  13  guinea  pigs  were  primed  with  DNP-OVA  (1.0  nag 
intraperitoneally  in  saline for 3  successive days)  and  1 wk later were given 
supplemental immunization with 50 #g of free carrier (either BGG or D-GL) 
in CFA. A control group received no supplemental carrier immunization. 3 wk 
later, secondary challenge was carried out with DNP conjugated to the carrier 
used for supplemental immunization (DNP-BGG or DNP-D-GL) at a dose of 
1.0 nag. As shown in  Fig.  1,  the guinea pigs which received 50 t~g of BGG in 
CFA as supplemental carrier immunization followed by secondary immuniza- 
tion with DNP-BGG displayed  anti-DNP  antibody responses  of considerable 
magnitude by days 4  and 7 after administration of DNP-BGG. In sharp con- 
trast, guinea pigs receiving D-GL or CFA alone for supplemental immunization 
did not have the  capacity to mount  anamnestic  responses  to DNP-D-GL or 
DNP-BGG,  respectively.  In  fact,  the  animals  challenged  with  DNP-n-GL 
displayed sharp declines in anti-DNP antibody levels, which is consistent with moo" 
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FIG.  1.  Failure to elicit hapten-specific antibody responses in strain 13  guinea pigs with 
DNP-D-GL. Strain 13  guinea pigs received a primary immunization with 3.0 mg of DNP- 
OVA, administered intraperitoneally in saline at week 0. 1 wk later supplemental immuniza- 
tion with 50 #g of either BGG or D-GL emulsified in CFA or saline in CFA was carried out. 
4 wk after primary immunization, the animals were challenged with 1.0 mg of either DNP- 
BGG or DNP-D-GL in saline. Serum anti-DNP antibody concentrations  just before challenge 
and on days 4  and 7 are illustrated. The numbers in parentheses refer to the numbers of 
animals in the given groups. 
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our previously reported  observations in  strain  13  guinea pigs similarly chal- 
lenged with DNP-L-GL (8). 
A  second experiment was carried out with  strain  2 guinea pigs in order to 
determine  the  extent  to which racemization from the D to L form of the co- 
polymer might have occurred as a result of conjugation with DNFB. Strain 2 
guinea pigs were immunized with either 100 ~g of DNP-L-GL in CFA, 100/~g 
of DNP-D-GL in CFA, or 1.0 lug of DNP-D-GL in CFA. Animals were bled  at 
14 and 21 days after immunization and serum anti-DNP antibody levels  were 
determined. As shown in Table I, there  were considerable anti-DNP antibody 
responses after immunization with DNP-L-GL, whereas no detectable antibody 
was made to DNP-D-GL even when 1.0 mg was  used as the immunizing dose. 
Thus, we were unable to demonstrate any i~mnunogenicity for guinea pigs on 
the part of the DNP-D-GL employed for these studies within  the limits of the 
methods  used  and  apparently no appreciable  degree of racemization has  oc- 
curred. 
TABLE I 
Failure to Flicit Hapten-Specific Antibody Responses in Strain 2 Guinea Pigs after Immuniza- 
tion with a DNP Conjugate of the Copolymer of D-Glutamic Acid and D-Lysine 
Group  Primary immunization 
No. of  Anti-DNP antibody-ABC-33* 
guinea pigs  Day 14  Day 21 
A  DNPso-I.-GL  100/zg  in CFA  4  100  471 
B  DNP53-D-GL  100#g in CFA  4  <1.0  <1.0 
C  DNP~-D-GL  1.0 mg in CFA  4  <1.0  <1.0 
*  ABC-33 is expressed as the dilution of antiserum at which 33% binding of the ligand, 
10-s~ I)NP-3H-epsilon-amino-N-caproic  acid, occurred. The geometric mean is presented. 
Specific  Suppression  of Anti-Hapten Antibody  Production in Guinea Pigs as a 
Result of Administration of DNP Conjugates o] Nonimmunogenic 
Carrier  Molecules 
(a) In the Elicitation of Augmented Hapten-Specific Primary Responses.--Two 
groups of strain 13 guinea pigs received a series  of injections of 1.0 mg of DNP- 
I)-GL or DNP-L-GL intraperitoneally in saline  daily for 3 successive days. A 
third group received saline injections during this period. 2 wk later,  all guinea 
pigs were immunized with 50 #g of OVA in  CFA in  the footpads.  This was 
followed 14 days thereafter  (day 0)  by primary immunization with  1.0 Ing of 
DNP-OVA in  saline  (200  #g intradermally  and  4  hr  later  800  #g intraperi- 
toneally). All animals were bled on days 0,  7,  14,  and 21  and determinations 
of serunl  anti-DNP  antibody levels  and  of numbers  of antigen-binding cells 
(ABC) in peripheral blood were made. A secondary challenge with DNP-OVA 
was carried out on day 14. As shown in Table II, guinea pigs which had received KATZ,  DAVIE~ PAUL,  AND  BENACERRA~"  207 
pretreatment with  saline  alone manifested typical augmented primary anti- 
DNP responses to DNP-OVA as a result of the preimmunization with uncon- 
jugated  OVA  in  CFA.  Furthermore, these  animals  displayed very marked 
secondary anti-DNP  antibody responses after the final challenge with DNP- 
OVA administered on day 14. In contrast, the synthesis of anti-DNP antibodies 
in response to DNP-OVA was markedly suppressed in guinea pigs which had 
received pretreatment with  either DNP-D-GL or DNP-L-GL. This was  true 
both for the augmented primary responses to DNP-OVA after carrier preim- 
munization  (OVA in  CFA)  and for anamnestic  responses to the DNP-OVA 
challenge  administered  on  day  14.  Furthermore,  before  initial  DNP-OVA 
immunization (day 0), the guinea pigs pretreated with either DNP copolymer 
had significantly fewer DNP-GPA-~SI  ABC  than did nonpretreated control 
animals.  This  suggests  that  the  unresponsive  state  involves  a  reduction  in 
precursors of anti-DNP  antibody-forming cells,  which the ABC  are believed 
to represent.  3 At day 21,  the number of ABC was still diminished in the pre- 
treated groups as  compared with  the  controls; the degree of depression was 
considerably less than the difference in serum anti-DNP binding activity at the 
same time. This apparent discrepancy may be due to at least two factors: (a) 
ABC,  as precursors of antibody-forming cells,  would be expected to recover 
from the tolerant state before appreciable increases in serum antibody levels 
would be observed. (b) The antibody assay used is dependent on both amount 
and affinity of antibody. If the pretreated groups had begun to recover from 
the  unresponsive  state,  they  would  most  likely  be  secreting  antibodies  of 
relatively low affinity. 
(b)  In  the  Elicitation  of  Hapten-Specific  Secondary  Responses.--Strain  13 
guinea pigs were given a 3 day primary immunization course consisting of 1.0 
mg daily of DNP-OVA intraperitoneally in saline.  2 wk later,  two groups of 
guinea pigs received an intervening series of injections of either DNP-I)-GL or 
DNP-L-GL. This consisted of 1.0 mg of hapten-copolymer conjugate in saline 
(200/zg intradermally followed 4 hr later by 800 #g intraperitoneally) admin- 
istered  daily  for  3  successive  days.  A  third  group  received no  intervening 
treatment. 2 wk later (day 0), all animals received a secondary immunization 
with 1.0 mg of DNP-OVA. Animals were bled on day 0 before secondary im- 
munization and 7 days later  (day 7)  for determinations of serum anti-DNP 
and anti-OVA  antibodies. The results are summarized in Table III and pre- 
sented graphically in Fig. 2.  Guinea pigs which received no intervening treat- 
ment  displayed  normal  levels  of  anti-DNP  antibodies  4  wk  after  primary 
immunization (day 0) and developed very brisk anamnestic anti-DNP responses 
by day 7 after secondary challenge. On the other hand, guinea pigs which had 
Davie, J. M., A. S. Rosenthal, and W. E. Paul. 1971. Receptors on immunocompetent 
cells. III. Specificity  and nature of receptors on 125I-DNP-GPA antigen-binding cells of im- 
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received  intervening injections of  DNP-I)-GL or  DNP-L-GL had  essentially 
no detectable anti-DNP antibody on day 0  and were incapable of mounting 
anamnestic  anti-DNP  responses.  That  this  suppressive  effect  was  hapten 
specific and not reflective of a  general depression of immune responsiveness is 
evidenced by the capacity of each guinea pig to mount primary and secondary 
TABLE II 
Specific Suppression of Anti-Hapten  Antibody Production in Strain 13 Guinea Pigs after Ad- 
ministration of DNP Conjugates of the Copolymers o( either  D-Glutamic Acid and D-Lysine 
or L-Glutamic Acid and L-Lysine 
Protocol* 
Group 
Pretreatment 
A  None 
B  DNP~3-D-GL 
C  DNPs0-L-GL 
No. of 
strain 13 
T 
Total ABC/10s 
Anfi-DNP antibody (#g/ml):~  peripheral blood cells[[ 
Day 0  Day 7  Day 14§  Day 21  Day 0  [  Day 21 
<0.10  12.3  297.9  4858.2  136.0  11,554.0 
<o.so  I  <0.10  1 <0,10  1  0.58  1  57,0  1  6300 
<0.10  1 <0.10  1 <0.20  t  3.6  I  480  1  4,388.0 
* Strain 13 guinea pigs received a 3-day series of injections of either DNPs~-I)-GL,  DNPs0- 
L-GL, or saline. 2 wk later all guinea pigs were immunized with 50/~g of OVA in CFA. This 
was followed 2 wk thereafter  by primary imnmnization with DNPs-OVA  (day 0).  A final 
challenge with DNPs-OVA was carried out on day 14. 
The data are expressed as geometric means. A comparison of the geometric mean anti- 
DNP antibody concentrations on day 7 and day 21 gave the following results: comparison 
of group A with groups B and C oll both day 7 and day 21 yielded P  values of  <0.001 in 
each case. 
§ Final challenge with  DNPs-OVA was administered  on day  14 after  each guinea pig 
was bled. 
II Heparinized peripheral  blood from individual guinea pigs was studied for ABC. The 
data presented represent the geometric mean numbers of ABC containing six or more grains 
per cell. A comparison of the geometric mean number of ABC on day 0 and day 21 gave the 
following results: on day 0, comparison of group A with groups B and C yielded P  values 
of  0.02 >  P  >  0.01 and  0.05 >  P  >  0.025, respectively;  comparison  of  group  B  with 
group  C yielded a P  value of 0.70 >  P  >  0.60. On day 21, comparison of group A with 
groups B and C and similarly, group B with group C, yielded P  values of  <0.001 in each 
case. 
anti-carrier (OVA) antibody responses irrespective of whether or not it had been 
subjected to intervening treatment with DNP copolymers. 
(c)  Effect of Administration  of DNP-D-GL  on Frequency of Antigen-Binding 
Cells.--Two  groups of  strain 13  guinea pigs were given a  3  day primary im- 
munization course of  1.0 mg daily of  DNP-OVA intraperitoneally in  saline. 
2 wk later, guinea pigs in one of  these DNP-OVA-primed groups and  a group 
of nonprimed animals were given a  series of injections of 1.0 mg of DNP-I~-GL 
intraperitoneally in saline for 3  successive days.  2  wk later all animals were 
sacrificed and the frequency of DNP-specific ABC in their mesenteric  lymph KATZ, DAVIE,  PAUL,  AND  BENACERRAF  209 
TABLE  III 
Specific  Suppression  of  Anti-DNP  Antibody  Responses  in  DNP-OVA-Primed  Strain  13 
Guinea Pigs az a Result of an Intervening  Treatment with DNP  Conjugates of the Copolymers 
of D-Glutamic Acid and D-Lysine  or of r~-Glutamic Acid and L-Lysine 
Anti-OVA antibody-AB  C-33  Anti-DNP antibody (/zg/ml)$  (/~g/ml)$ 
Group 
No. of 
animals 
Protocol* 
Intervening 
treatment 
A  None 
B  DNP53-D  -GL 
C  DNP6o-L-GL 
Day 0  Day 7  Boost 
25.8  986.8  961.0 
<0.10  0.12  0.02 
<0.10  <0.10  0 
Day 0  Day  7  Boost 
4.9  139.8  134.9 
1.3  42.9  41.6 
12.5  193.7  181.2 
* Strain  13  guinea pigs were given a  3  day primary immunization course with DNPs- 
OVA. 2 wk later groups of guinea pigs received an intervening series of injections for 3 days 
of either DNPsa-D-GL,  DNPs0-L-GL,  or saline. 2 wk later all  animals were boosted with 
DNPs-OVA (day 0). 
The data are expressed as geometric means. Boost represents the increase in mean anti- 
body levels from day 0 to day 7. A comparison of the geometric mean anti-DNP antibody 
concentrations on day 0 and day 7 gave the following results: comparison of group A with 
groups B and C on both day 0 and day 7 yielded P  values of <0.001  in each case. 
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Fro. 2. DNP-specific tolerance induced in DNP-OVA-primed guinea pigs as a result of an 
intervening treatment with DNP-D-GL or DNP-L-GL. Strain 13 guinea pigs received a pri- 
mary immunization with 3.0  mg of DNP-OVA administered intraperitoueally in saline at 
week 0. 2 wk later, an intervening treatment with 3.0 mg of either DNP-D-GL or DNP-L-GL 
in saline or saline alone was carried out. 4 wk after primary immunization, the animals were 
challenged with 1.0 mg of DNP-OVA in saline. Serum anti-DNP and anti-OVA antibody 
concentrations just before challenge and on day 7 are illustrated. The numbers in parentheses 
refer to the number of animals in the given groups. 210  NONIMMUNOGENIC  ttAPTEN-COPOLYMERS 
nodes and in the mesenteric lymphs nodes of normal control guinea pigs was 
determined. The geometric mean numbers of ABC observed in the DNP-OVA- 
primed guinea pigs which received no intervening DNP-D-GL treatment and 
in the virgin controls were  1332 and 818 per l06 cells,  respectively. In sharp 
contrast,  the frequency of ABC in the guinea pigs  treated with DNP-D-GL 
2  wk  after  primary  immunization with DNP-OVA  and  in  the  nonprimed 
guinea pigs treated with DNP-D-GL was 104 and 34 per 106 cells, respectively. 
Such  striking  reductions  in  frequency of observed DNP-specific ABC  after 
administration of DNP-D-GL support the concept that the tolerant state re- 
sulting  from such  treatment  involves diminution  in  the  number of effective 
precursors of DNP-specific antibody-forming cells. 
Stimulation of Anti-Hapten Antibody Production  by a Nonimmunogenic DNP 
Copolymer after the Transfer of Immunocompetent  Strain 2 Cells 
into Primed Strain 13 Recipients  ("Allogeneic Effect") 
In our previous report (19)  we described a phenomenon (allogeneic effect) 
in which,  as a  result of induction of a  graft-versus-host  reaction, primed im- 
munocompetent cells could be stimulated to produce large quantities of specific 
anti-hapten and anti-carrier antibodies even in the absence of further antigenic 
challenge. Moreover, when secondary antigenic challenge was administered at 
an optimal time after allogeneic cell transfer (6 days) the anti-hapten responses 
were greatly heightened even in cases where the secondary challenge was made 
with a  hapten conjugate of a  carrier antigenically unrelated to that used for 
primary immunization. Thus, it appeared that the stimulatory properties of the 
allogeneic effect obviated the necessity for carrier specificity in the elicitation 
of hapten-specific antibody responses. The present experiment was designed to 
test the possibility of eliciting hapten-specific secondary responses, through this 
allogeneic  effect,  when challenge is made with a  hapten conjugate of  a  non- 
immunogenic carrier molecule. 
550 X  106 lymph node and spleen cells from strain 2 guinea pigs,  which had 
been immunized 3  wk previously with  CFA,  were transferred intravenously 
into DNP-OVAoprimed  strain  13 recipients.  6 days later,  two groups of re- 
cipients were challenged with DNP-BGG or DNP-D-GL; a third group received 
no secondary challenge. As shown in Table IV and Fig. 3, the allogeneic effect 
results in  a  significant increase in  serum  anti-DNP  antibody concentrations 
between  day  6  and  day  13  after  transfer  in  the  absence  of any  additional 
antigenic stimulation. Even more striking, however, is the heightened stimula- 
tion  of  anti-DNP  antibody  production  after  the  administration  of  DNP- 
heterologous carrier conjugates,  regardless of whether the carrier molecule is 
highly immunogenic  (BGG)  or  nonimmunogenic  (D-GL). Determinations  of 
indirect  PFC/106  spleen  cells  corroborated  the  results  of  serum  anti-DNP 
antibody  levels  in  that  there  was  a  clear  quantitative  difference between KATZ,  DAVIE,  PAUL,  AND  BENACERRAF  211 
recipients which had been subjected to secondary challenge with either DNP- 
BGG  or  DNP-B-GL  and  those  which  had  not;  furthermore,  the  average 
PFC/106 in the spleens of guinea pigs challenged with DNP-D-GL was identical 
with that in the spleens of guinea pigs challenged with DNP-BGG. This sug- 
gests,  perhaps,  that  the lower serum anti-DNP antibody levels of  recipients 
challenged with  DNP-D-GL  compared  to  those  challenged with  DNP-BGG 
TABLE IV 
Elleltation of Antibody Responses to a Nonimmunogenic DNP-Carrier Conjugate in Strain 13 
Guinea Pigs during the Course of the Allogeneic Ej~evt after Transfer of Strain 2 
Lymph Node and Spleen Cells 
Group 
Indirect 
Protocol*  Anti-DNP antibody (/~g/ml);  PFC/10s 
spleen cells§ 
No. of strain 2  Secondary  No. of  Day after transfer 
donor cells  strain 13  Day 17 after 
transferred  immunization  recipients  Day 6  Day 13  Boost  transfer 
A  550 X  106  DNP23-BGG  5  29.2  1084.7  1055.5  153 
B  550 )< 106  DNPsa-D-GL  5  11.3  672.8  661.5  153 
C  550 )<  106  None  5  23.8  276.5  252.7  47 
* 550  ;K  106 lymph node and spleen cells from strain 2 guinea pig donors immunized 
with CFA were transferred  to individual strain 13 recipients which had been immunized 3 
wk earlier with DNPs-OVA. Recipients were boosted 6 days after transfer with either DNP28- 
BGG or DNP~-D-GL. 
:~ The data are  expressed as geometric means.  Boost  represents  the  increase in mean 
antibody levels from the day of boosting (day 6 after transfer)  to 7 days later (day 13). A 
comparison of the increases in geometric mean anti-DNP antibody concentrations from day 
6 to day 13 after transfer gave the following results: comparison of group A with group B 
yielded a P value of 0.50 >  P  >  0.40. Comparison of group A with group C and, similarly 
Group B with group C, yielded P values of 0.05 >  P  >  0.025 in each case. 
§ The recipients in each group were sacrificed on day 17 after  transfer  and individual 
spleens were assayed for anti-DNP PFC using TNP-conjngated SRBC  as  indicator.  Fa- 
cilitated  plaques  were  developed with rabbit anti-guinea pig "r2-globulin. The geometric 
mean number of PFC/106 spleen cells of each group is presented. A comparison of the geo- 
metric mean numbers of PFC gave the following results: comparison of group A with group 
C and, similarly group B with group C, yielded P values of 0.005 >  P  >  0.001 in each case. 
may  reflect  binding and  subsequent  clearance  of  antibody by  an  antigen 
molecule which is poorly metabolized. 
Failure of Allogeneic Effect in Nonprimed Guinea Pigs to Modify tIapten-Specific 
Immunosuppression by Nonimmunogenic DNP Copolymers 
(a)  Induction of Allogeneic Effect  1 Day after  Administration of DNP-D-GL 
or DNP-L-GL.--The preceding study demonstrated clearly that,  when given 
at  the  optimal  time  after  induction of  the  allogeneic effect,  DNP-D-GL  is 
capable of evoking hapten-specific anamnestic responses in DNP-OVA-primed 212  NONIMMUNOGENIC HAPTEN-COPOLYMERS 
guinea pigs. This sharply contrasts with the results in the first experiments in 
this paper, where,  in the absence of allogeneic cell transfer, it was shown  that 
administration  of  DNP-D-GL  caused  marked  suppression  of  anti-DNP  re- 
sponses in both primed and nonprimed guinea pigs. Thus,  studies were made 
to determine the  effect of inducing  GVH  reactions in  nonprimed  guinea pigs 
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Fro. 3. Stimulation of anti-DNP antibody production as a result of transfer of immuno- 
competent strain 2 cells into primed strain 13 recipients.  The effect of secondary antigenic 
challenge with DNP-BGG and DNP-D-GL.  550 X  106 strain 2 lymph node and spleen cells 
were injected intravenously into strain 13  recipients primed 3 wk earlier with DNP-OVA. 
Recipients were either not boosted  or boosted with 1.0 nag of DNP-BGG or DNP-D-GL  in 
saline 6 days after transfer. Serum anti-DNP antibody concentrations just before secondary 
immunization and on days 7 and 11 are illustrated. The numbers in parentheses refer to the 
numbers of animals in the given groups. 
either before or  after administration of  these nonimmunogenic  DNP  copoly- 
mers.  Strain  13  and  strain  2  guinea  pigs  received  1.0  mg  of  DNP-D-GL  or 
DNP-L-GL intraperitoneally in saline for 3 successive days. 24 br after the last 
dose, the treated guinea pigs and normal strain 13  control guinea pigs received 
200  X  106 lymph node and spleen cells from CFA-immunized strain 2  donors. 
Thus,  strain  13  guinea pigs were recipients of allogeneic cells while the strain 
2  guinea pigs were recipients of syngeneic cells. 2  or 3  wk  after cell transfer, KATZ,  DAVIE,  PAUL,  AND  BENACERRAF  213 
all guinea pigs were immunized with 50 #g of OVA in CFA in the footpads. 
This was followed 2 wk later (day 0) by immunization with 1.0 mg of DNP-OVA 
in saline (200 #g intradermally and in 4 hr 800/zg intraperitoneally). A final 
challenge with DNP-OVA was made on day 14 or day 15. Results of one study 
are  presented in  Table V  and  Fig.  4.  Thus,  control strain  13  recipients  of 
allogeneic cells displayed typical augmented primary anti-DNP  responses to 
TABLE  V 
Specific  Suppression  of  Anti-Hapten  Antibody  Production  in  Strain  13  and  Strain  2 
Guinea Pigs after  Administration  of  a  DNP  conjugate of  the  Nonimmunogeniv  Copolymer 
of  D-Glutamic  Acid  and  D-Lysine  and  Failure  to  Modify  the  Tolerance with 
the Allogeneic Effect 
Group 
Protocol* 
[  No.  and 
Pretreatment  strain of 
--  --  guinea plg.~s 
None  [ 5 Strain 13 
DNP53-D-GL [ 5 Strain 13 
DNPsa-D-GL [ 5 Strain 2 
Anti-DNP antibody Q~g/ml)$ 
Indirect  Total 
Anti-OVA  I  PFC/  ABC/ 
antibody-ABC-33  [  10¢  106 
(#g/ml)~  spleen  spleen 
cells§  __cells§ 
Day0  .....  Day7  Day 11  Day 22  Day0  D~y  D~y  Day 25  Day 25 
<0.10  5.5  [  16.1  13129.1  1125  6398  8707  142  21,500 
<0.10  <0.10  <0.10  0.26  1394  7884  9677  <1  3,200 
<0.10l  <0.10  I  <0.I0  [  0.49[  866  ]  5830[  7531  [  12  2,100 
* 200 x l0 s lymph node and spleen cells from strain 2 guinea pig donors weIe transferred to allogeneic strain 
13 and syngeneic strain 2 recipients which had completed a 3-day series of injections of DNP~-D-GL or normal 
saline 24 hr before transfer. 3 wk later, all recipients were immunized with 50/~g of OVA in CFA followed 2 wk 
thereafter by immunization with DNPs-OVA (day 0). A final challenge with DNPs-OVA was made on day 15. 
The data are expressed as geometric means. A comparison of the geometric mean anti-nNP antibody con- 
centrations on day 7 and day 22 gave the following results: comparison of group A with groups B and C  on both 
day 7 and day 22 yielded P  values of <0.001 in each case. 
§ All guinea pigs were sacrificed on day 25 and individual spleens were assayed for anti-DNP PFC and ABC. 
Facilitated  plaques were developed with rabbit anti-guinea pig  72-globulin using TNP-conjugated  SRBC  as 
indicator. ABC were determined by radioautography using DNP-GPAA~6I as antigen. The data are expressed 
as geometric means. A comparison of the geometric mean numbers of PFC gave the following results: compari- 
son of group A with groups B and C yielded P  values of <0.001 in each case; comparison of group B  with group 
C yielded a P  value of 0.025 >  P  >  0.020.  A  comparison of the geometric mean numbers of ABC yielded the 
following results: comparison of group A with groups B  and C yielded P  values of 0.005  >  P  >  0.001 and P  < 
0.001, respectively; comparison of group B  with group C yielded a P  value of 0.40 >  P  >  0.30. 
DNP-OVA  as  a  result of carrier preimmunization,  and brisk  anamnestic re- 
sponses to the final DNP-OVA challenge administered on day 15. In contrast, 
all guinea pigs which had initially received DNP-D-GL failed to mount either 
augmented primary or appropriate  anamnestic  antibody responses to DNP- 
OVA. This was true of both the strain 13 recipients of allogeneic cells and the 
strain 2 recipients of syngeneic cells.  Again, the anti-OVA antibody responses 
were normal pointing out the hapten-specific nature of the unresponsiveness. 
The  significantly  depressed  levels  of  anti-DNP  antibody-forming cells  and 
DNP-specific  antigen-binding  cells  in  spleens  of  guinea  pigs  treated  with 
DNP-D-GL argues strongly for a central mechanism of tolerance. 214  NONIMMUNOGENIC  tIAPTEN-COPOLYMERS 
The  data from  a  second study is summarized  in Table VI.  All guinea pigs 
in this experiment were strain  13  recipients of allogeneic cells. Again, control 
guinea  pigs manifested  augmented  primary and  anamnestic  anti-DNP  anti- 
body responses to DNP-OVA,  whereas guinea pigs previously treated, in  this 
case with either DNP-D-GL or DNP-L-GL, were markedly suppressed in their 
ability to respond. 
(b) Induction  of Allogeneic Effect 6 Days before Administration  of DNP-D-GL 
or DNP-L-GL.--200  X  106 lymph node and spleen cells from strain 2  guinea 
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FIG. 4. Failure of allogeneic effect to modify DNP-specific  tolerance induced by the ad- 
ministration of DNP-D-GL  or I)NP-L-GL 1 day before cell transfer. At wk 0, strain 13 and 
strain 2 guinea pigs were  injected intraperitoneally with 3.0  mg of either DNP-D-GL  or 
DNP-L-GL in saline, or saline alone; 24 hr later all guinea pigs received 200  )  106 lymph 
node and spleen cells from strain 2 donors. 2 or 3 wk after cell transfer, all recipients were 
immunized with 50/zg of OVA emulsified in CFA. This was followed 2 wk thereafter by pri- 
mary immunization with 1.0 mg of DNP-OVA in saline (day 0). A final challenge with 1.0 mg 
of DNP-OVA in saline was carried out on day 14 or day 15. Serum anti-DNP and anti-OVA 
antibody concentrations just before primary DNP-OVA immunization and on days 7, 11, and 
22 are illustrated. The numbers  in parentheses refer to the numbers  of animals in the given 
groups. 
pig donors were  transferred intravenously to nonimmune strain 13  guinea pig 
recipients. These animals were injected 6 days later with 1.0 mg of DNP-BGG, 
DNP-D-GL,  or DNP-L-GL intraperitoneally in saline for 3  successive days. A 
control group of recipients received no pretreatment. 2  wk later, all recipients 
were immunized with 50/~g of OVA in CFA. This was followed 2 wk thereafter 
(day 0)  by immunization with  1.0 mg  of DNP-OVA  in  saline (200  #g  intra- 
derma!ly and 4  hr later 800/~g intraperitoneally). A final challenge with DNP- 
OVA was made on day 14. The results are summarized in Table VII and pre- 
sented graphically in Fig. 5. Those recipients not given the tolerizing injections 
or  injected  with  DNP-BGG  were  capable  of  mounting  augmented  primary 
and  anamnestic  anti-DNP  antibody  responses  to  DNP-OVA.  On  the  other KATZ, DAVIE~ PAUL, AND  BENACERRAF  215 
hand,  those  recipients  which  had  been  treated  with  either  DNP-D-GL  or 
DNP-L-GL were rendered tolerant to the DNP determinant even though they 
had received allogeneic immunocompetent cells previously. Thus, induction of 
graft-versus-host reactions in nonprimed guinea pigs fails to abrogate the strong 
tolerogenic effects  of  these  nonimmunogenic DNP  copolymers  regardless  of 
TABLE VI 
Specific  Suppression  of Anti-Hapten  Antibody  Production  in  Strain  13  Guinea  Pigs  after 
Administration of DNP Conjugates of the Copolymers of either D-Glutamic Acid 
and D-Lysine or L-Glutamic Acid and L-Lyslne and Failure to Modify the 
Suppression with the Allogeneic Effect 
Protocol*  Anti-DNP antibody  ~ug/ml)$ 
Group 
A 
B 
C 
Pretreatraent 
None 
DNP~-D-GL 
DNPs0-L-GL 
Allogeneic  transfer 
200 X  106 
strain 2 cells 
200 X  106 
strain 2 cells 
200 X  106 
strain 2 cells 
No. of 
strain 13  Day 0 
recipients 
5  <0.10 
5  <0.10 
5  <0.10 
Day 7 
3.8 
<0.10 
<0.10 
Day 14§ 
161.1 
<0.10 
0.22 
Day 21 
2978.4 
0.~ 
7.4 
* 200 X  106 lymph node and spleen ceils from strain 2 guinea pig donors were transferred 
to aUogeneic strain 13 guinea pig recipients which had received a 3-day series of injections 
of DNP58-D-GL, DN'Ps0-L-GL, or normal saline 24 hr before transfer. 2 wk later, all guinea 
pigs were immunized with 50 #g of OVA in CFA. This was followed 2 wk thereafter  by im- 
munization with DNPs-OVA (day 0). A final challenge with DNPs-OVA was made on day 
14. 
The data are expressed as geometric means. A comparison of the geometric mean anti- 
DNP antibody concentrations on day 7 and day 21 yielded the following results: on day 7, 
comparison of group A with groups B and C yielded P  values of <0.001 in each  case. On 
day 21, comparison of group A with groups B and C yielded P  values of P  <  0.001 and 
0.005 >  P  >  0.001, respectively; comparison of groups B and C yielded a P  value of 0.01 
>  P  >  0.005. 
§ Final challenge with DNPs-OVA was administered  on day 14 after  each guinea  pig 
was bled. 
whether allogeneic cell transfer is carried out before or shortly after administra- 
tion of these compounds. 
DISCUSSION 
Two sharply contrasting effects on immunocompetent cells may be brought 
about by the administration of nonimmunogenic  DNP-carrier conjugates: (a) 
the induction of a state of DNP-specific unresponsiveness after administration 
of these substances to nonprimed guinea pigs and to guinea pigs which have 216  NONIM-MUNOGENIC  HAPTEN-COPOLYMERS 
been previously primed with  an immunogenic conjugate, DNP-OVA.  (b)  The 
elicitation by  a  nonimmunogenic DNP  copolymer  of  secondary anti-hapten 
antibody responses in primed guinea pigs undergoing an appropriately timed 
graft-versus-host reaction. 
For the purposes of this discussion, we will define "hapten-specific tolerance" 
as the specific suppression of anti-hapten antibody responses to conjugates of 
TABLE  VII 
Failure of Previously Induced Allogeneic t~ffect to Prevent Suppression  of Anti-DNP Responses 
in Strain 13 Guinea Pigs Subsequently Administered  DNP conjugates of the 
Copolymers of D-Glutamic Acid and D-Lysine or of L-Glutamic Acid and 
L-Lysine 
Protocol*  No. of  Anti-DNP antibody (/Ig/ml):~ 
Group  strain 13 
Pretreatment  recipients  Day 0  Day 7  Day 14§  Day 21  Boost 
A  None  5  <0.10  0.49  109.9  3170.8  3170.7 
B  DNP23-BGG  5  0.14  6.7  83.0  950.0  949.9 
C  DNP~3-D-GL  5  <0.10  <0.10  <0.10  0.49  0.39 
D  DNPs0-L-GL  4  <0.10  0.12  0.25  1.77  1.67 
* 200  X  106 lymph node and spleen cells from strain 2 guinea pig donors were trans- 
ferred to nonimmune  allogeneic strain 13 guinea pig recipients. 6 days after allogeneic trans- 
fer, groups of recipients were given a 3-day series of injections of either DNP23-B  GG, DNP~8- 
D-GL, DNPs0-L-GL, or normal saline. 2 wk later,  all recipients were immunized with 50 
~g of OVA in CFA. This was followed 2 wk thereMter by immunization  with DNPs-OVA 
(day 0). A final challenge with DNPs-OVA was carried out on day 14. 
J~ The data are expressed as geometric means. Boost represents the increase in mean anti- 
body levels from day 0 to day 21. A comparison of the geometric mean anti-DNP antibody 
concentrations on day 14 and day 21 gave the following results: on day 14, a comparison of 
group A with group B yielded a P value of 0.80 >  P  >  0.70; comparison of group A with 
groups C and D and, similarly, group B with groups C and D yielded P  values of  <0.001 
in each case. On day 21, comparison of group A with group B yielded a P  value of 0.20 > 
P  >  0.10; comparison of group A with groups C and D and, similarly, group B with groups 
C and D yielded P values of <0.001 in each case. 
§ Final challenge with  DNPs-OVA was administered  on day  14 after  each guinea pig 
was bled. 
a  given hapten  resulting from  the  prior  administration of  the  haptenic de- 
terminant alone or of the hapten conjugated to an unrelated carrier.  The in- 
duction of tolerance to hapten-carrier conjugates has been described by several 
investigators (34-36). In general, impaired anti-hapten antibody responses were 
restricted  to  the hapten-carrier conjugates used for  tolerance induction. The 
tolerant animals displayed either no suppression or only a  transient decrease 
of anti-hapten responses when challenged with the hapten coupled to a carrier 
unrelated to  that  used  in the  paralysis-inducing regimen.  Such  experiments 
(34-36), therefore, cannot be considered examples of hapten-specific tolerance. KATZ, DAVIE, PAUL~ AND  BENACERRAF  217 
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FIG. 5. Failure of allogeneic effect to modify DNP-specific  tolerance induced by the ad- 
ministration of DNP-D-GL or DNP-L-GL 6 days after aUogeneic cell transfer. 200  X  106 
lymph node and spleen cells from strain 2 donors were injected intravenously into nonimmune 
strain 13 recipients at week 0. 6 days later, the recipients were injected intraperitoneally  with 
3.0 mg of either DNP-BGG, DNP-D-GL, or DNP-L-GL in saline, or saline alone. 2 wk later, 
all recipients were immunized with 50 #g of OVA emulsified in CFA. This was followed 2 wk 
thereafter by primary immunization with 1.0 mg of DNP-OVA in saline (day 0). A final chal- 
lenge with 1.0 mg of DNP-OVA in saline was carried out on day 14. Serum anti-DNP antibody 
concentrations just before primary DNP-OVA immunization and on days 7, 14, and 21 are 
illustrated. The numbers  in parentheses refer to the numbers of animals in the given groups. 
These various  observations may be  reconciled and  understood  in  terms  of 
the two-cell theory of immune responsiveness. If the precursors of anti-hapten 
antibody-forming  cells  are  equated  with  bone  marrow-derived  lymphocytes 
and  carrier reactive helper  cells with  thymus-derived lymphocytes, the unre- 218  NONIMMUNOGENIC  ttAPTEN-COPOLYMERS 
sponsiveness to challenge with the hapten-carrier used for tolerance induction 
may reflect tolerance in  either or both cell populations.  On  the  other hand, 
hapten-specific tolerance, as  defined above, requires a  state of specific unre- 
sponsiveness in the bone marrow-derived precursors of antibody-forming cells. 
Chiller et al. have recently demonstrated that in mice the rate of induction and 
duration  of  tolerance differ markedly in  the  thymus  and  bone marrow  cell 
populations (18). In the latter, larger doses and a longer induction period are 
required and the duration is shorter. These differences account for the earlier 
difficulty in achieving hapten-specific tolerance. 
In the present studies, however, a marked degree of DNP-specific tolerance 
was readily induced with moderate doses of DNP conjugates of nonimmuno- 
genic copolymers of glutamic acid and lysine. This was reflected not only by 
dramatic  reductions  in  serum  anti-DNP  antibody  levels  after  subsequent 
challenge but also by a diminished frequency of DNP-specific antigen-binding 
cells and of anti-DNP antibody-secreting cells,  which is evidence for a central 
tolerance  mechanism.  Further,  after  the  tolerance-inducing  regimens,  the 
frequency of DNP-specific antigen-binding cells was lower than in nontreated 
controls, suggesting either a reduction in the number of specific precursors of 
anti-DNP  antibody-forming cells  or the prior saturation  of the receptors on 
these cells with the DNP determinants of the tolerogen. 
A  possible  explanation for the  ease of tolerance induction with  the DNP 
conjugates of noninmmnogenic copolymers and also for other  non- or weakly 
immunogenic substances  may be  the  lack  of the simultaneous occurrence of 
immunization and tolerance induction when these substances are administered. 
If, as we suggest, the weak immunogenicity of a substance is primarily deter- 
mined by (a)  the absence or scarcity of effective thymus-derived helper cells 
specific for that  substance,  and  (b)  the  relative inability of the  material  to 
activate bone marrow-derived cells without the cooperation of thymus-derived 
cells,  then tolerance induction by these nonimmunogenic materials  and their 
DNP conjugates may be interpreted to result from direct interaction in the ap- 
propriate dose range with specific precursors of antibody-forming cells without 
intervening helper cells.  Indeed, it appears  that  the precursors of antibody- 
forming cells are susceptible to tolerance induction by the DNP copolymers we 
have employed even if the animal in which  they reside has previously been 
primed with DNP-OVA. 
Although the simplest explanation of the data is that no specific helper cells 
exist  for  these  DNP  copolymers,  one  could  also  explain  these  findings  by 
envisaging the existence of nonimmunogen-specific helper cells which are always 
rendered tolerant by interaction with these types of substances. An additional 
alternative is to postulate the existence of two subpopulations of helper cells, 
one  subserving  the  function  of  stimulating  responses  in  the  precursors  of 
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precursors leading to tolerance induction in those cells.  For nonimmunogens, 
one would postulate either a complete absence of the stimulatory helper cells 
or a marked excess of the suppressive type. Recent studies by Baker et al. in 
pneumococcal polysaccharide responses  suggest  the  possibility  that  in  mice 
thymus-derived cells exert a suppressive effect on anti-Sin antibody synthesis 
(37). 
These concepts may explain the puzzling phenomenon described by some 
investigators studying the  "termination" of tolerance to protein antigens by 
administration of modified or cross-reactive proteins (38-40). In those experi- 
ments,  the simultaneous administration  of even very small quantities of the 
tolerated protein prevented termination of the unresponsive state. It has been 
postulated  that  the mechanism in  the  termination  of tolerance involves the 
presentation of the determinants of the tolerated protein to precursors of anti- 
body-forming cells  through  the  action  of helper  cells  specific for  the  cross- 
reactive or altered protein (18). In this set of circumstances, injection of the 
tolerated protein simultaneous with the cross-reactive protein should lead to a 
potent  suppressive  effect on  the  precursors  of  antibody-forming cells  either 
because of the absence of helper cells specific for the tolerated substance or 
because of the action of a suppressive type of thymus-derived cell. 
In striking contrast with the tolerogenic properties of DNP  conjugates of 
nonimmunogenic copolymers for normal animals discussed above, the elicitation 
of a  GVH reaction in  a  DNP-OVA-primed  recipient renders the  animal  re- 
fractory to  tolerance induction by DNP-I)-GL and permits this  molecule to 
behave as an immunogen capable of stimulating a strong anti-DNP secondary 
response. The response obtained with DNP-D-GL is  comparable to that  ob- 
served  with  DNP-BGG  under  identical  experimental  conditions.  We  have 
previously suggested that the response to DNP-BGG under this set of circum- 
stances may reflect a direct stimulation of precursors of antibody-forming cells 
by antigen when a  simultaneous stimulation of such cells by a  GVH reaction 
is occurring (19). The observation of McCullagh (41)  that adult rats tolerant 
to SRBC nevertheless are stimulated to form an anti-sheep erythrocyte anti- 
body  response  by  administration  of  allogeneic immunocompetent  cells  and 
SRBC is analogous  to the allogeneic effect described in  this  and our earlier 
study (19). Although  the precise mechanism(s)  by which  the  GVH reaction 
causes these effects is not known, the ability to obtain a response with DNP-I)- 
GL  strengthens  the  foregoing hypothesis in  that  helper  cells for  this  non- 
immunogenic compound most likely do not exist or are not functional.  Our 
failure  to  obtain  evidence  of  activation  of  precursors  of  specific  antibody- 
forming cells with the nonimmunogenic DNP copolymers in nonprimed guinea 
pigs undergoing GVH reactions is unexplained. Nevertheless, it is consistent 
with  our  failure  to  obtain  heightened  responses  to  an  immunogenic  DNP 220  NONIMMUNOGENIC HAPTEN-COPOLYMERS 
conjugate under the same circumstances. A more detailed consideration of this 
observation is presented in another publication.  4 
This study also raises the issue of the definition of an immunogen in terms 
of the two-cell concept of antibody formation. A molecule incapable of being 
bound  by,  or  of  stimulating,  thymus-derived helper  cells  is  expected to be 
endowed with only very weak immunogenicity, but to be an excellent tolerogen. 
Such a molecule should stimulate only very low antibody responses and little 
cellular proliferation by specific bone marrow cells in a narrow range of antigen 
concentrations. At higher concentrations tolerance will be induced. Thus, when 
used at tolerogenic levels or when relatively insensitive assays for antibodies 
are used,  such  a  molecule will  appear  operationally nonimmunogenic. These 
compounds, however, may behave as excellent haptens when bound to carrier 
molecules capable of stimulating thymus-derived helper cells. The nonimmuno- 
genic copolymers used in this study and the well-studied pneumococcal poly- 
saccharides may be considered typical examples of such molecules which are 
nonimmunogenic for thymus-derived cells and yet may bind to bone marrow- 
derived  precursors  of  antibody-secreting  cells  with  resulting  tolerance  or 
production  of  small  amounts  of  antibodies  according  to  the  experimental 
conditions. 
The experiments presented in  this  study and  the  considerations discussed 
above imply that  the interaction of antigenic determinants and receptors of 
precursors  of  antibody-forming  cells  may  lead  to  very  different  outcomes 
determined by the differences in form in which  the antigen is presented or, 
particularly, by the state of the cell at the time of interaction. Thus, in non- 
primed and primed animals interaction in the adequate dose range of DNP on 
nonimmunogenic  carriers  with  specific  precursors  of  antibody-forming  cells 
leads to an inactivation of those cells. On the other hand, the direct or indirect 
stimulation  of precursors of antibody-forming cells by GVH reactions allows 
these  cells  to  be  stimulated  by the  nonimmunogenic DNP  conjugate.  This 
latter  stimulatory outcome may well proceed by a  mechanism  akin  to  that 
which normally operates for the stimulation of these cells  through the inter- 
action  of  immunogenic  conjugates  and  helper  cells.  This  process  might  be 
mediated by products of stimulated thymus-derived cells destined to regulate 
the stimulation of antibody-forming cell precursors by antigen. More detailed 
analysis  of this  allogeneic effect may provide insight  into the nature of col- 
laborative interactions between two cell types and of the factors produced in 
the development of immune responses. 
Finally,  it  is  conceivable that  the  stimulation  of precursors  of  antibody- 
forming cells by normally nonimmunogenic substances during GVH reactions 
4 Katz, D. H., W. E. Paul, and B. Benacerraf. 1971. Carrier function in anti-hapten anti- 
body responses. V. Analysis of cellular events in the enhancement of antibody responses by 
the  "allogeneic effect" in DNP-OVA primed guinea pigs challenged with a  heterologous 
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may well have significant pathogenetic implications. For example, host antigens 
which may be tolerated as a result of unresponsiveness in the helper cell popula- 
tion,  might  stimulate  the  development  of  autoantibodies,  as  is  observed in 
various disease states, by virtue of their capacity to directly stimulate precursors 
of  antibody-forming  cells  when  the  latter  are  subjected  to  potent  stimuli 
similar to those observed in the GVH reaction. 
SUMMARY 
Administration of nonimmunogenic 2,4-dinitrophenyl  (DNP)  conjugates of 
copolymers of D or  L-glutamic acid  and  lysine  (GL)  induces  hapten-specific 
tolerance in  nonimmune and  DNP-ovalbumin-primed strain  13  guinea  pigs. 
This tolerant state is evidenced by depressed anti-DNP  antibody synthesis in 
response to challenge with DNP-ovalbumin and by a diminished frequency of 
DNP-specific antigen-binding  cells and of anti-DNP  antibody-secreting cells. 
Such  a  nonimmunogenic compound  (DNP-D-GL)  will nevertheless  elicit  a 
DNP-specific  anamnestic  antibody  response  when  administered  at  an  ap- 
propriate  time  to  DNP-ovalbumin-primed  guinea  pigs  undergoing  a  graft- 
versus-host  reaction.  These  experiments  are  discussed  in  terms of  a  two-cell 
theory of stimulation of antibody responses. 
The authors gratefully acknowledge the expert technical assistance of Miss Lula Jackson, 
Mr. Robert McClesky, and Mrs. Barbara Johnson. 
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